Literature DB >> 1541125

Oxygen supplementation during air travel in patients with chronic obstructive lung disease.

B W Berg1, T A Dillard, K R Rajagopal, W J Mehm.   

Abstract

The objective of this study was to quantitate the effects of O2 supplementation by nasal cannula (NC) and Venturi mask (VM) on PaO2 in patients with chronic obstructive pulmonary disease (COPD) during acute hypobaric exposure, simulating a commercial jet aircraft cabin. We conducted a crossover intervention trial in which subjects served as their own controls in an ambulatory outpatient pulmonary disease service of a tertiary care military medical center and a hypobaric research facility. The subjects were a volunteer sample of 18 men with stable severe COPD, not requiring long-term O2 therapy, and uncomplicated by hypercapnea or cardiac disease. Mean age was 68 years, and mean FEV1 was 0.97 L (31.3 percent predicted). We exposed patients to conditions equivalent to 8,000 feet in a hypobaric chamber. Radial artery catheters provided blood samples at ground level and 8,000 feet. O2 was sequentially administered at 8,000 feet by NC at 4 L/min and 24 percent or 28 percent VM. We describe changes in blood gas data from baseline values and between interventions. O2 at 4 L/min NC flow at 8,000 feet caused PaO2 to increase from 47.4 +/- 6.3 mm Hg to 82.3 +/- 14 mm Hg (n = 18), an increase of 34.9 +/- 14.8 mm Hg. Supplementation of O2 by 24 percent VM caused PaO2 at 8,000 feet to increase by 12.7 +/- 3.8 mm Hg. Twenty-eight percent VM caused PaO2 at 8,000 feet to increase by 19.7 +/- 8.2 mm Hg. Changes in PaO2 with 4 L/min NC were greater than those with either VM. The increase with 28 percent VM was greater than that caused by 24 percent VM (p less than 0.05). Compared with ground level, 4 L/min NC increased mean PaO2 by 9.9 +/- 12.6 mm Hg; 24 percent and 28 percent VM did not cause mean PaO2 to increase above ground level values. We describe a range of capability of familiar O2 therapy devices to increase PaO2 to levels that will maintain tissue oxygenation of patients during acute altitude exposure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541125     DOI: 10.1378/chest.101.3.638

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Holidays and cystic fibrosis.

Authors:  A Verma; M E Dodd; C S Haworth; A K Webb
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations.

Authors: 
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

3.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

4.  Effects of commercial air travel on patients with pulmonary hypertension air travel and pulmonary hypertension.

Authors:  Nareg Roubinian; C Gregory Elliott; Christopher F Barnett; Paul D Blanc; Joan Chen; Teresa De Marco; Hubert Chen
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

5.  Effect of simulated commercial flight on oxygenation in patients with interstitial lung disease and chronic obstructive pulmonary disease.

Authors:  L M Seccombe; P T Kelly; C K Wong; P G Rogers; S Lim; M J Peters
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

6. 

Authors:  Francisco Ríos Tejada
Journal:  FMC       Date:  2009-01-06

7.  Prediction of hypoxaemia at high altitude in children with cystic fibrosis.

Authors:  P J Oades; R M Buchdahl; A Bush
Journal:  BMJ       Date:  1994-01-01

Review 8.  [Air travel and respiratory diseases].

Authors:  Francisco García Río; Luis Borderías Clau; Ciro Casanova Macario; Bartolomé R Celli; Joan Escarrabill Sanglás; Nicolás González Mangado; Josep Roca Torrent; Fernando Uresandi Romero
Journal:  Arch Bronconeumol       Date:  2007-02       Impact factor: 4.872

Review 9.  Chronic obstructive pulmonary disease * 11: fitness to fly with COPD.

Authors:  A O C Johnson
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

10.  Respiratory function and blood gas variables in cystic fibrosis patients during reduced environmental pressure.

Authors:  Oliver Thews; Birthe Fleck; Wolfgang E S Kamin; Dirk-Matthias Rose
Journal:  Eur J Appl Physiol       Date:  2004-08       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.